When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PBYI - Puma Bio up 5% premarket on Nerlynx data in heavily pretreated breast cancer patients
Puma Biotechnology Inc
Puma Biotechnology (NASDAQ:PBYI) is up 5% premarket on light volume in response to results from an ongoing open-label Phase 2 basket study, SUMMIT, evaluating Nerlynx (neratinib), combined with Roche's Herceptin (trastuzumab) and AstraZeneca's Faslodex (fulvestrant), in patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer. The data were presented at the San Antonio Breast Cancer Symposium.
More news on: Puma Biotechnology, Inc., Healthcare stocks news, Stocks on the move,